Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterologyINDIANAPOLIS, Aug. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Morphic Holding, Inc. (NASDAQ: MORF). Morphic is a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic disease ...